journal logo

Welcome to Leukemia

Leading journal covering all aspects of the research and treatment of leukemia and allied diseases.


  • crispr-cas9

    NEW COLLECTION: Since its discovery as part of the adaptive immune system in bacteria, CRISPR-Cas9 has become an invaluable tool for genome editing with the potential to transform cancer therapies. This collection of articles from Leukemia and other related Springer Nature journals explores use of CRISPR-Cas9 technology to date and explores future possibilities. Further submissions welcome.

  • car-t

    NEW COLLECTION: Cancer therapy using chimeric antigen receptor (CAR)-T-cells is one of the most exciting recent developments in cancer therapy. This collection highlights key research published in this area from Leukemia and other related Springer Nature journals. Further submissions welcome.

  • resistance

    NEW COLLECTION: Metastatic cancer is ultimately resistant to virtually all systemic therapies and continues to kill more than 10 million people per year around the world. This collection of articles from Leukemia and other related Springer Nature journals explores how treatment resistance arises in cancer. Further submissions welcome.

Leukemia is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


leu collection image

Classification and nomenclature of hematologic diseases

The World Health Organization (WHO) Classification of Tumours provides a definitive classification of all tumours, worldwide. This is essential to underpin the diagnosis and treatment of cancer, as well as research and education. Without it, clinical trial results could not be compared between countries, research results could not be evaluated collectively and epidemiological studies based on cancer registration would be impossible. The classification will help move the field forward by being based on a forwardlooking multidisciplinary effort grounded in genetic advances, with an eye on worldwide applicability. An overview of the classification and its salient features are provided in two typescripts, which cover the classification of myeloid and histiocytic/dendritic neoplasms and the classification of lymphoid neoplasms. Added to this is the recent 'HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions'. In this typescript a group of experts under auspices of the Human Genome Organization’s (HUGO) Gene Nomenclature Committee (HGNC) proposes using double colons (::) as the official designation for fusion genes. The Leukemia Editors strongly support the HGNC recommendation and request authors use the HGNC nomenclature in submissions to Leukemia and other journals. The goal of HUGO and HGNC is to provide unique symbols and names for human gene loci including protein coding genes, non-coding RNA genes and pseudogenes with the purpose of unambiguous scientific communication.